Clinical Trials

Every new drug, therapy, and medical device that reaches patients must first pass through clinical trials. There are currently over 500,000 studies registered on ClinicalTrials.gov. The clinical data generated at each phase is what regulators, physicians, and payers use to make decisions, making trial readouts some of the most closely watched events in the biopharmaceutical industry.

Our reporting tracks developments across every stage of the drug development pipeline: Phase 1 first-in-human trials, Phase 2 dose-ranging studies, large-scale Phase 3 efficacy trials, regulatory submissions, and post-marketing studies. Trial design, clinical trial enrolment, endpoint data, patient safety, and drug safety are all covered across the therapeutic areas generating the most activity, including oncology, obesity and metabolic disease, rare diseases, autoimmune disorders, neuroscience, cardiovascular disease, and infectious disease.

Trial types in focus include GLP-1 receptor agonist trials, CRISPR and gene editing studies, CAR-T cell therapy data, antibody-drug conjugate results, radiopharmaceutical trials, and biosimilar equivalence studies. Methodology is evolving rapidly too. Adaptive and decentralised trial designs, randomised controlled trials, and AI in patient selection and real-world evidence generation are reshaping how studies are run.

Regulatory context is central to every story, covering PDUFA dates, FDA advisory committee meetings, accelerated approval, breakthrough therapy designation, fast track designation, priority review, and investigational new drug (IND) applications. Sources include published clinical data, ClinicalTrials.gov filings, peer-reviewed research, and expert commentary.

Explore the latest clinical trial articles on this page. Follow this page for the readouts that move markets and shape treatment decisions, or subscribe to get updates delivered to you.

Don’t wait for the media to pick up your story. Be the media.